Table 5.

Univariate and penalized multivariate Fine & Gray regression analysis. Penalization was adopted to adjust for potential over‐fitting and was obtained using Firth's correction. Response variable was time to progression from ASCT and was adjusted for the competitive risk of death

	HR	95% Lower confidence limit for HR	95% Upper confidence limit for HR	Probability > χ2	% Of explained variation
Univariate Fine & Gray regression analysis
Variable
IPFP (≥3 vs. <3)	1·656	0·655	3·931	0·2621	0·71
MSKCC (≥2 vs. <2)	1·229	0·511	3·244	0·6560	0·02
Age (≥45 years vs. <45 years)	1·850	0·701	4·448	0·1840	0·95
Chemosensitive (no vs. yes)	1·138	0·267	3·365	0·8353	0·03
Response to first line chemotherapy (Rel + early rel vs. ref)	1·833	0·620	7·827	0·3312	0·23
Gender (male vs. female)	0·378	0·143	0·908	0·0355	3·85
Bulk disease >5 cm (yes vs. no)	1·064	0·379	2·618	0·8980	0·01
Number of previous chemotherapy lines (>2 vs. 2)	0·939	0·307	2·398	0·9025	0·01
B Symptoms (yes vs. no)	0·850	0·360	2·084	0·7132	0·16
18FFDG‐PET status prior to ASCT (positive vs. negative)	2·543	1·072	6·106	0·0327	2·90
Serum LDH (abnormal vs. normal)	1·858	0·758	4·389	0·1604	1·96
Total					13·97
Penalized multivariate Fine & Gray regression analysis
Variable
IPFP (≥3 vs. <3)	2·047	0·746	5·683	0·1745
MSKCC (≥2 vs. <2)	0·495	0·152	1·641	0·2530
Age (≥45 years vs. <45 years)	2·203	0·816	5·474	0·1081
Response to first line chemotherapy (Rel + early rel vs. ref)	1·885	0·516	8·363	0·3723
Gender (male vs. female)	0·377	0·143	0·914	0·0413
18FFDG‐PET status prior to ASCT (positive vs. negative)	2·560	1·044	6·354	0·0443
Serum LDH (abnormal vs. normal)	1·648	0·637	4·134	0·3023

FEAM, fotemustine, etoposide, cytarabine, melphalan; IPFP, International Prognostic Factors Projectscore; MSKCC, Memorial Sloan‐Kettering Cancer Center score; ASCT, autologous stem cell transplantation; Rel, relapse; Ref, refractory; PET, positron emission tomography; LDH, lactate dehydrogenase; HR, hazard ratio; ¹⁸FDG‐PET, ^18Ffluorodeoxyglucose‐positron emission tomography.